Welcome to our dedicated page for Senseonics news (Ticker: SENS), a resource for investors and traders seeking the latest updates and insights on Senseonics stock.
Senseonics Holdings, Inc. (SENS) is a medical technology company in the surgical and medical instrument manufacturing industry, focused on glucose monitoring products for people with diabetes. Company news frequently centers on its long-term implantable continuous glucose monitoring (CGM) systems, Eversense 365 and Eversense E3, which use an under-the-skin sensor, a smart transmitter, and a mobile app to deliver frequent glucose readings.
News updates for SENS often include financial results and revenue updates, such as preliminary unaudited revenue announcements and quarterly earnings reports. These disclosures provide information on revenue trends, new patient growth, and other operating metrics related to the rollout and adoption of Eversense 365 in the United States and other markets.
Investors and observers can also find corporate and capital markets news, including announcements about a 1-for-20 reverse stock split, special stockholder meetings, and the company’s decision to transfer its stock exchange listing from the NYSE American to the Nasdaq Global Select Market. SEC-related press releases, such as those tied to Form 8-K filings, often accompany these events.
Another key category of Senseonics news involves commercialization and partnership developments. The company has reported on its collaboration with Ascensia Diabetes Care and the planned transition of Eversense 365 commercialization and distribution to Senseonics, as well as its work with Sequel MedTech to integrate the Eversense 365 CGM with the twiist automated insulin delivery system. These updates describe how Eversense technology is being deployed and supported in the diabetes care ecosystem.
Visitors to the SENS news page can review these press releases and related updates to follow Senseonics’ progress in long-term implantable CGM technology, its commercialization strategy for Eversense products, and its ongoing financial and corporate reporting. Regularly checking this page can help readers track how the company’s medical device platform and public company activities evolve over time.
Senseonics Holdings, Inc. (NYSE American: SENS), specializing in long-term, implantable continuous glucose monitoring systems, plans to participate in the virtual H.C. Wainwright Global Investment Conference. Management will engage in one-on-one meetings on September 15, 2021, with a presentation webcast available starting September 13, 2021, at 7:00 AM ET. Access to the on-demand webcast will be provided on the company’s website. Senseonics is dedicated to transforming diabetes management with its Eversense® CGM products, which offer real-time glucose data via a mobile app.
Senseonics Holdings reported second quarter 2021 revenue of $3.3 million, significantly up from $0.26 million in Q2 2020. U.S. revenue was $0.98 million, while international revenue reached $2.31 million. The company raised $50 million through an equity offering, mainly for debt service. However, net loss expanded to $180.32 million or $0.42 per share, largely due to increased accounting charges. Senseonics projects 2021 global net revenue between $12 million to $15 million.
Senseonics Holdings, Inc. (NYSE-American: SENS) has announced its plan to release second quarter 2021 financial results on August 9, 2021, after market close. The company will hold a conference call at 4:30 p.m. Eastern Time to discuss its performance, with a concurrent webcast available on their website. Senseonics specializes in developing long-term, implantable continuous glucose monitoring systems, such as the Eversense and Eversense XL, which provide real-time glucose data to users via a smartphone app.
Senseonics Holdings has granted equity to new employees as per its 2019 Inducement Plan. On July 1, 2021, the Compensation Committee approved 66,000 non-qualified stock options for five new non-executive employees, with an exercise price of $3.50 per share. The vesting schedule includes 25% on the first anniversary of their start date and the rest monthly over three years, contingent on continued service. The company aims to expand its Eversense continuous glucose monitoring (CGM) system for diabetes management.
Senseonics Holdings, Inc. (NYSE American: SENS) presented new data from the PROMISE Study regarding its Eversense CGM System at the American Diabetes Association’s 81st Annual Scientific Sessions. The findings indicate that the next-generation device demonstrates safety and accuracy comparable to the current 90-day sensor with extended usage up to 180 days. Key metrics include a mean absolute relative difference (MARD) of 9.1% and high hypoglycemia alert detection rates. The Eversense system enhances user experience by offering discreet alerts and a rechargeable transmitter.
Senseonics Holdings (SENS) announced positive results from the PROMISE Study for its Eversense CGM System, showcasing its accuracy and safety over a 180-day period. The study revealed an overall mean absolute relative difference (MARD) of 9.1% for the primary sensor and a 93% hypoglycemic alert detection rate. The company is awaiting regulatory feedback from US and European agencies regarding its pre-market submissions. The Eversense CGM System, now available in the US and Europe, is significant for patients managing diabetes.
Senseonics Holdings reported financial results for Q1 2021, with revenues reaching $2.85 million, a significant increase from $0.04 million in Q1 2020. Revenue outside the U.S. accounted for $2.53 million. Notably, the company decreased its operating loss by $32.52 million year-over-year, while net loss rose to $249.51 million, largely due to non-cash accounting charges. Senseonics expects 2021 global net revenue between $12 million and $15 million. The company also strengthened its balance sheet by raising $175 million from financing transactions.
Senseonics Holdings, Inc. (NYSE-American: SENS) announced plans to release its Q1 2021 financial results after market close on May 13, 2021. A conference call will follow at 4:30 p.m. ET to discuss performance, which will also be available via webcast. Senseonics specializes in implantable continuous glucose monitoring (CGM) systems to aid diabetes management. Their products include the Eversense® and Eversense® XL CGM systems. More details will be accessible on their website.
Senseonics Holdings, Inc. (NYSE American: SENS) has granted equity to new employees as part of its 2019 Inducement Plan. On April 1, 2021, five non-executive employees were awarded stock options totaling 62,000 shares at an exercise price of $2.58, the closing price on that day. The options will vest over a four-year period contingent on continued service. Senseonics continues to advance its Eversense Continuous Glucose Monitoring (CGM) System, which measures glucose levels for individuals aged 18 and older and aims to expand its market reach globally.
Senseonics Holdings reported financial results for 2020, with Q4 revenue at $3.9 million, down from $9.0 million in Q4 2019. U.S. sales were $0.4 million, while international sales were $3.5 million. The company raised $175 million in equity offerings early 2021 to bolster its balance sheet. Net loss for Q4 2020 was $101.6 million, increasing from $35.6 million in Q4 2019. For the full year, total revenue was $4.9 million, significantly down from $21.3 million in 2019. Looking ahead, 2021 guidance estimates revenue between $12 million and $15 million.
FAQ
What is the current stock price of Senseonics (SENS)?
What is the market cap of Senseonics (SENS)?
